Study Group: Council Members who Purchase the Da Vinci Robotic System
Council Members in this Study Group: 132
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Guy BernsteinPresident
The Center for Urologic Care
Guy Bernstein, MD, is the President and a practicing Urologist at the Center for Urologic Care in Bryn Mawr, Pennsylvania. Dr. Bernstein is experienced in all aspects of urology with special interest in erectile dysfunction, male infertility, incontinence,...
- Russell Freid
Urologist
LAWRENCEVILLE UROLOGYRussell Freid, MD, is an Urologist at Lawrenceville Urology. Dr. Freid is busy in practicing all areas of urology and also conducting several research clinical trials. The Lawrenceville Urology practice is located in central New Jersey and serves a diverse...
- Kenneth Morris
Senior Vice President, CFO and Treasurer
DUKE UNIVERSITY HEALTH SYSTEM, INC.Kenneth Morris is Senior Vice President, CFO and Treasurer at Duke University Health System. Reporting to the President and CEO of the System, Mr. Morris provides top-level management and oversight of all financial operations including Accounting, Financial...
Ravi MunverVice Chairman, Chief of Minimally Invasive Surgery
HACKENSACK UNIVERSITY MEDICAL CENTERRavi Munver, MD, is the Vice Chairman and Chief of Minimally Invasive and Robotic Urologic Surgery at Hackensack University Medical Center, New Jersey. He is an Associate Professor of Urology and is a Faculty at Touro University College of Medicine and...
- Peter Davis
President and Chief Executive Officer
ST JOSEPH HOSPITALPeter Davis, MPH, MHA, FACHE, is the President and Chief Executive Officer at the St. Joseph Hospital and Trauma Center in Nashua, which is a part of the St. Joseph Hospital System in New Hampshire. He has over 35 years of experience in hospital administration,...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Prostate Cancer Genetic Testing - Is it real or is it boutique lab work?
January 20, 2009
Analysis by: Mitchell Bamberger, Attending Physician,Clarient Launches Gene Expression Test for Prostate Cancer | www.medcompare.com
Genetic testing for clinically significant prostate cancer is vital to allow clinicians to treat patients. This appears to be a step in the right direction, although it does not seem this will have a major impact for the majority of cases. The study represents only a small subgroup of patients that may have some benefit from this new molecular biology test.
-
Intermittent hormonal therapy for Prostate Cancer: Is it here yet?
January 2, 2009
Analysis by: Mitchell Bamberger, Attending Physician,Finnish Multicenter Study Comparing Intermittent To Continuous Androgen Deprivation For Advanced Prostate Cancer | www.medicalnewstoday.com
prostate cancer, hormonal therapy, intermittent treatemtent
-
Prostate cancer DNA vaccine trial - a necessary step
December 29, 2008
Analysis by: Mitchell Bamberger, Attending Physician,Approval From The Swedish Medical Products Agency To Start A Clinical Trial Using A Xenogenic PSA DNA Vaccine | www.medicalnewstoday.com
prostate cancer, vaccine, dna
-
Robotic Prostatectomy ?Too soon to tell?
May 29, 2008
Analysis by: Mitchell Bamberger, Attending Physician,Mixed Outcomes in Laparoscopy for Prostates | www.nytimes.com
The data gives a mixed review regarding the robotic assisted radical prostatectomy for prostate cancer. There is a clear advantage in regards to a significantly decreased risk of bleeding, post operative pain, and earlier return to normal activities. However, the data does not show a clinical advantage in cancer cure or clinically significant improvement in cancer control. Much more data is needed over a longer period of time. The article does not mention surgeon experience, i.e. those who have done many robotic prostatectomies vs. a surgeon with a limited experience. Nor does the article mention post operative complications such as preservation of erectile function and continence control.
-
Novel immunotherapy for prostate cancer
April 16, 2008
Analysis by: Mitchell Bamberger, Attending Physician,Cell Genesys Announces Encouraging Results from Phase 1/2 Trial of GVAX Immunotherapy for Prostate Cancer in Recurrent Disease | www.pipelinereview.com
Novel therapy for advance recurrent prostate cancer that does not rely upon traditional standard hormone therapy. This has the potential for men to continue to be sexually active while receiving treatment for advanced disease. It also opens the door to other therapeutic interventions.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Facility, Non-Academic/Community Hospital
- Non-Academic Community Hospital or Clinic
- Office Based Private Practice or Clinic
- Integrated Healthcare Delivery Network (IDN)
- Facility, Academic Medical Center
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Director
- Physician - Division Head
- Chief Executive Officer
- Physician - Department Chair
- Supply Chain Director
- President
- Owner
Related Study Groups
GLG Live Meetings with this Study Group's Leading Experts (?)
July 11, 2006 | New York
GLGi: Robotic Surgery in UrologyGLG Webcasts & Teleconferences
Leading Experts in Council Members who Purchase the Da Vinci Robotic System have not participated in any GLG webcasts.